; (ii) subject to terms including— (I) that the Secretary shall cease any payment installments under a transitional subscription contract if the sponsor does not— (aa) ensure commercial availability of the antimicrobial drug within 30 days of receiving first payment under the contract; (bb) identify, track, and publicly report drug resistance data, and trends using available data related to the antimicrobial drug; (cc) develop and implement education and communications strategies, including communications for individuals with limited English proficiency and individuals with disabilities, for health care professionals and patients about appropriate use of the antimicrobial drug; (dd) submit a plan for registering the antimicrobial drug in additional countries where an unmet medical need exists, which such plan may be consistent with the Stewardship and Access Plan (SAP) Development Guide (2021); (ee) subject to subparagraph (B), ensure a reliable drug supply chain, thus leading to an interruption of the supply of the antimicrobial drug in the United States for more than 60 days; or (ff) make meaningful progress toward completion of Food and Drug Administration-required postmarketing studies, including such studies that are evidence based; and (II) other terms as determined by the Secretary; and (iii) if— (I) a phase 3 clinical study has been initiated for the antimicrobial drug